Skip to main content
. 2012 Mar 15;54(12):1778–1783. doi: 10.1093/cid/cis307

Table 1.

Characteristics of Participants and Duration of Follow-up

Characteristic TIV (n = 69) Placebo (n = 46)
Age group, No. (%)
 6–8 years 19 (28) 16 (35)
 9–11 years 41 (59) 27 (59)
 12–15 years 9 (13) 3 (7)
Female sex, No. (%) 30 (43) 23 (50)
Median duration of follow-up, days 272 272
Mean no. of individuals per household 3.7 3.6

Abbreviation: TIV, trivalent inactivated influenza vaccine.